Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Ligand Pharmaceuticals (LGND)

Ligand Pharmaceuticals stockholders elect eight directors and approve 2002 Plan restatement

Neutral Impact 2 of 5 shareholder Written later

At its June 5, 2026 annual meeting, Ligand Pharmaceuticals stockholders elected all eight director nominees to terms expiring in 2027 and approved an amended and restated 2002 Stock Incentive Plan. Stockholders also ratified Ernst & Young LLP as auditor for fiscal 2026 and approved a non-binding advisory vote on executive pay. The filing reports voting results only and does not report financial results.

Key points

  • All eight director nominees were elected, including Jason M. Aryeh, Todd C. Davis and Martine Zimmermann, Pharm.D.
  • Proposal 4 to approve the amended and restated 2002 Stock Incentive Plan passed with 16,643,281 votes for and 870,556 against.
  • Ernst & Young LLP was ratified as independent registered public accounting firm for the year ending December 31, 2026, with 18,526,515 votes for.
  • Non-binding say-on-pay proposal was approved with 16,497,712 votes for and 1,021,948 against.

The filing

CompanyLigand Pharmaceuticals (LGND)
Form8-K, current report
Filed with the SECJun 9, 2026, 4:02 PM ET
Accession number0000886163-26-000038

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 09, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.